GlaxoSmithKline PLC (GSK): Price and Financial Metrics
GlaxoSmithKline PLC (GSK)
Today's Latest Price: $41.70 USD
Updated Jun 5 4:10pm
Add GSK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
GSK Stock Summary
- GSK has a market capitalization of $112,237,681,516 -- more than approximately 98.37% of US stocks.
- Glaxosmithkline Plc's stock had its IPO on July 9, 1986, making it an older stock than 92.35% of US equities in our set.
- The volatility of Glaxosmithkline Plc's share price is greater than that of merely 3.62% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to GSK, based on their financial statements, market capitalization, and price volatility, are IBM, DHR, MMM, SNY, and TXN.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK Stock Price Chart More Charts
GSK Price/Volume Stats
| Current price | $41.70 | 52-week high | $48.25 |
| Prev. close | $41.65 | 52-week low | $31.43 |
| Day low | $41.62 | Volume | 2,778,969 |
| Day high | $42.07 | Avg. volume | 4,352,618 |
| 50-day MA | $40.70 | Dividend yield | 4.46% |
| 200-day MA | $42.71 | Market Cap | 104.61B |
GlaxoSmithKline PLC (GSK) Company Bio
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
GSK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $41.70 | $22.98 | -45% |
Below please find a table outlining a discounted cash flow forecast for GSK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Glaxosmithkline Plc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Glaxosmithkline Plc, consider:
- GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.8% of tickers in our DCF set.
- The weighted average cost of capital for the company is 8. This value is greater than only 22.7% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -47% |
| 1% | -46% |
| 2% | -45% |
| 3% | -45% |
| 4% | -44% |
| 5% | -44% |
Want more companies with a valuation profile/forecast similar to that of Glaxosmithkline Plc? See COO, IQV, DXCM, ZTS, and HAE.
Loading social stream, please wait...